Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

2.245 +0.065 (+2.98%)
Streaming Delayed Price Updated: 3:08 PM EDT, Oct 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
21 22 Next >
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Shares Fell Today: What's Going On?
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares closed lower on Monday potentially following the company's announcement of Dan Kirby as Chief Commercial Officer. 
Via Benzinga
Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
What's Wrong With Iovance Biotherapeutics Stock?
Via The Motley Fool
Where Will Iovance Biotherapeutics Be in 5 Years?
Via The Motley Fool
Prediction: This Stock Will Beat the Market in 2025
Via The Motley Fool
Peering Into Iovance Biotherapeutics's Recent Short Interest
 
Via Benzinga
Meet the Growth Stock That Could Soar 280%, According to Wall Street Analysts
Via The Motley Fool
3 Stocks That Could Turn $1,000 Into $5,000 by 2030
A handful of bullish factors are converging at the right time in the right way for all three of these companies. 
Via The Motley Fool
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Shares Are Falling Today: What's Going On?
Shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) are trading lower Friday. The company announced the inducement stock option grants under Nasdaq Listing Rule 5635(c)(4). 
Via Benzinga
3 Mid-Cap Stocks That Could Take Off in 2025
Via The Motley Fool
Is Iovance Biotherapeutics Stock a Millionaire Maker?
Via The Motley Fool
Got $1,500? Buy Iovance Biotherapeutics Now and Don't Look Back
Via The Motley Fool
A Peek at Iovance Biotherapeutics's Future Earnings
 
Via Benzinga
Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
If I Could Only Buy 3 Stocks in the Last Month of 2024, I'd Pick These
These windows of opportunity aren't likely to remain open for much longer. 
Via The Motley Fool
Is Iovance Biotherapeutics Stock a Buy?
The biotech is making important breakthroughs, but is that enough? 
Via The Motley Fool
2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?
Via The Motley Fool
3 Monster Stocks to Hold for the Next 10 Years
Just be ready to ride out some inevitable turbulence along the way. 
Via The Motley Fool
Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
2 Innovative Stocks That Could Deliver Outsize Returns
Via The Motley Fool
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More
Via The Motley Fool
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024
Iovance also to Participate in Upcoming November Conferences 
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Why Iovance Biotherapeutics Stock Triumphed on Thursday
With a cutting-edge melanoma drug now on the market, the company is positioned for a breakout. 
Via The Motley Fool
3 Reasons to Buy Iovance Biotherapeutics Stock Like There's No Tomorrow
This biotech's growth story is going to start moving faster, and soon. 
Via The Motley Fool
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.